Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dynamic Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- Early Breast Cancer (ADAPTela)

NCT07242352 is registered in ClinicalTrials.gov with Women's Cancer Study Group GmbH as lead sponsor.

NCT NCT07242352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07242352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dynamic Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- Early Breast Cancer (ADAPTela)
Lead sponsor
Women's Cancer Study Group GmbH
Phase
Phase 3
Overall status
Recruiting
Start date
April 29, 2026
Completion date
September 30, 2033
Enrollment
1,520 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, hr+/her2- breast cancer